The Use of Anticonvulsant Adjuncts to Treat Alcohol Withdrawal Syndrome in Older Adults.
alcohol
anticonvulsant
benzodiazepines
geriatric
older adult
withdrawal
Journal
Canadian geriatrics journal : CGJ
ISSN: 1925-8348
Titre abrégé: Can Geriatr J
Pays: Canada
ID NLM: 101579189
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
22
3
2022
Statut:
epublish
Résumé
We evaluated the prescribing practices of anticonvulsant (AC) adjuncts to benzodiazepines in managing Alcohol Withdrawal Syndrome (AWS). We also examined the prescription of relapse prevention agents for Alcohol Use Disorder (AUD), and adverse events related to AWS treatment. Records were reviewed retrospectively pertaining to medically ill adults aged 60 and above with AWS and admitted to a medicine or hospitalist unit of a Canadian centre between June 2013 and June 2018. Duration and dosing of benzodiazepine, dosing and type of AC and AUD agent, and adverse events were collected. A multivariable regression model was employed. 83 encounters were included in the study and 28 were prescribed an AC. The amount and duration of benzodiazepine administered were not statistically different between the benzodiazepine only and the AC adjunct groups, once severe AWS complications were accounted for. Five new prescriptions of traditional AUD agents were provided on discharge. No AC-associated adverse events occurred. AC adjuncts for AWS did not decrease the amount of benzodiazepine administered nor shorten the duration of treatment. Their routine use is not supported by our findings. Our study highlights a missed opportunity for AUD agents to be prescribed during hospitalization.
Sections du résumé
Background
UNASSIGNED
We evaluated the prescribing practices of anticonvulsant (AC) adjuncts to benzodiazepines in managing Alcohol Withdrawal Syndrome (AWS). We also examined the prescription of relapse prevention agents for Alcohol Use Disorder (AUD), and adverse events related to AWS treatment.
Methods
UNASSIGNED
Records were reviewed retrospectively pertaining to medically ill adults aged 60 and above with AWS and admitted to a medicine or hospitalist unit of a Canadian centre between June 2013 and June 2018. Duration and dosing of benzodiazepine, dosing and type of AC and AUD agent, and adverse events were collected. A multivariable regression model was employed.
Results
UNASSIGNED
83 encounters were included in the study and 28 were prescribed an AC. The amount and duration of benzodiazepine administered were not statistically different between the benzodiazepine only and the AC adjunct groups, once severe AWS complications were accounted for. Five new prescriptions of traditional AUD agents were provided on discharge. No AC-associated adverse events occurred.
Conclusions
UNASSIGNED
AC adjuncts for AWS did not decrease the amount of benzodiazepine administered nor shorten the duration of treatment. Their routine use is not supported by our findings. Our study highlights a missed opportunity for AUD agents to be prescribed during hospitalization.
Identifiants
pubmed: 35310475
doi: 10.5770/cgj.25.544
pii: cgj-25-32
pmc: PMC8887711
doi:
Types de publication
Journal Article
Langues
eng
Pagination
32-39Informations de copyright
© 2022 Author(s). Published by the Canadian Geriatrics Society.
Déclaration de conflit d'intérêts
CONFLICT OF INTEREST DISCLOSURES We have read and understood the Canadian Geriatrics Journal’s policy on conflicts of interest disclosure and declare the following interests: Peter Chan is on the advisory board for Janssen-Ortho. The other authors have no conflicts of interest to declare.
Références
Ment Health Clin. 2019 Jan 4;9(1):1-5
pubmed: 30627496
Alcohol Alcohol. 1992 Mar;27(2):153-8
pubmed: 1524606
Psychosomatics. 2017 Jul - Aug;58(4):331-342
pubmed: 28501289
Mayo Clin Proc. 2008 Mar;83(3):274-9
pubmed: 18315992
JAMA Intern Med. 2014 Jan;174(1):70-7
pubmed: 24190578
Eur Addict Res. 2003 Apr;9(2):59-64
pubmed: 12644731
Front Psychiatry. 2019 May 07;10:228
pubmed: 31133886
CNS Drugs. 2017 Feb;31(2):87-95
pubmed: 28101764
Cochrane Database Syst Rev. 2010 Mar 17;(3):CD005064
pubmed: 20238337
Vital Health Stat 10. 2014 Feb;(260):1-161
pubmed: 24819891
Alcohol Health Res World. 1998;22(1):13-24
pubmed: 15706728
Curr Psychiatry Rep. 2016 Sep;18(9):87
pubmed: 27488204
Psychiatry (Edgmont). 2005 May;2(5):25-31
pubmed: 21152146
Psychopharmacol Bull. 2019 Feb 15;49(1):17-27
pubmed: 30858636
Alcohol Clin Exp Res. 2001 Sep;25(9):1324-9
pubmed: 11584152
Drugs Real World Outcomes. 2016 Mar;3(1):7-12
pubmed: 27747801
Addict Behav. 2006 Sep;31(9):1628-49
pubmed: 16472931
Crit Care Clin. 2017 Jul;33(3):559-599
pubmed: 28601135
Ann Pharmacother. 2006 Mar;40(3):441-8
pubmed: 16507623
Am J Drug Alcohol Abuse. 2018;44(4):418-425
pubmed: 28981333
J Exp Pharmacol. 2017 Feb 09;9:13-21
pubmed: 28223849
Prim Care Companion CNS Disord. 2019 Aug 22;21(4):
pubmed: 31461226
Arch Gen Psychiatry. 2008 Oct;65(10):1214-21
pubmed: 18838638
Br J Addict. 1989 Nov;84(11):1353-7
pubmed: 2597811
Alcohol Alcohol. 2010 Mar-Apr;45(2):143-5
pubmed: 20019070
Lancet. 2018 Sep 22;392(10152):1015-1035
pubmed: 30146330
J Am Geriatr Soc. 2014 Aug;62(8):1551-5
pubmed: 24962514
Alcohol. 2014 Jun;48(4):375-90
pubmed: 24657098
Can J Hosp Pharm. 2011 Nov;64(6):436-45
pubmed: 22479099
Alcohol Clin Exp Res. 2019 Jan;43(1):158-169
pubmed: 30403402
Handb Clin Neurol. 2014;125:123-31
pubmed: 25307572
Drugs. 2015 Mar;75(4):353-65
pubmed: 25666543
Am J Psychiatry. 2011 Jul;168(7):709-17
pubmed: 21454917
Expert Opin Investig Drugs. 2018 Jan;27(1):113-124
pubmed: 29241365
J Gen Intern Med. 2002 May;17(5):349-55
pubmed: 12047731
Alcohol Clin Exp Res. 2009 Sep;33(9):1582-8
pubmed: 19485969
Exp Gerontol. 2012 Jun;47(6):411-6
pubmed: 22575256
CNS Drugs. 2015 Apr;29(4):293-311
pubmed: 25895020